File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Antibiotic resistance in community-acquired pneumonia caused by Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus, and Acinetobacter baumannii

TitleAntibiotic resistance in community-acquired pneumonia caused by Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus, and Acinetobacter baumannii
Authors
Issue Date2009
PublisherAmerican College of Chest Physicians. The Journal's web site is located at http://www.chestjournal.org
Citation
Chest, 2009, v. 136 n. 4, p. 1119-1127 How to Cite?
AbstractAntimicrobial therapy is the mainstay of management for community-acquired pneumonia (CAP). Accordingly, the choices of treatment are influenced by the likely etiologies, local resistance patterns of the pathogens, as well as patient factors. As the leading cause of acute CAP, the susceptibility patterns of Streptococcus pneumoniae have greatly influenced antimicrobial agents and dosage recommended for empirical treatment of this condition. The worldwide emergence of community-acquired methicillin-resistant Staphylococcus aureus has also led to discussion of this pathogen in recent revisions of the international CAP guidelines. This pathogen is important because of its resistance to antibiotics commonly recommended for the empirical treatment of CAP and the association with a rapidly fatal form of pneumonia characterized by tissue necrosis, pulmonary hemorrhage, and rapid progression to respiratory failure. In tropical regions of Australia and Asia, CAP due to Acinetobacter baumannii is also increasingly recognized. This review discusses their recent epidemiology, microbiology, clinical features, and treatment of CAP caused by these antimicrobial-resistant pathogens. © 2009 American College of Chest Physicians.
Persistent Identifierhttp://hdl.handle.net/10722/157560
ISSN
2015 Impact Factor: 5.94
2015 SCImago Journal Rankings: 3.176
ISI Accession Number ID
Funding AgencyGrant Number
Research Fund for the Control of Infectious Diseases (RFCID) of the Health, Welfare and Food Bureau of the Hong Kong SAR Government
UDF Project-Research Centre of Emerging Infectious Diseases
Funding Information:

Funding/Support: This review was supported by research grants from the Research Fund for the Control of Infectious Diseases (RFCID) of the Health, Welfare and Food Bureau of the Hong Kong SAR Government and from the UDF Project-Research Centre of Emerging Infectious Diseases.

References

 

DC FieldValueLanguage
dc.contributor.authorHo, PLen_US
dc.contributor.authorCheng, VCCen_US
dc.contributor.authorChu, CMen_US
dc.date.accessioned2012-08-08T08:51:15Z-
dc.date.available2012-08-08T08:51:15Z-
dc.date.issued2009en_US
dc.identifier.citationChest, 2009, v. 136 n. 4, p. 1119-1127en_US
dc.identifier.issn0012-3692en_US
dc.identifier.urihttp://hdl.handle.net/10722/157560-
dc.description.abstractAntimicrobial therapy is the mainstay of management for community-acquired pneumonia (CAP). Accordingly, the choices of treatment are influenced by the likely etiologies, local resistance patterns of the pathogens, as well as patient factors. As the leading cause of acute CAP, the susceptibility patterns of Streptococcus pneumoniae have greatly influenced antimicrobial agents and dosage recommended for empirical treatment of this condition. The worldwide emergence of community-acquired methicillin-resistant Staphylococcus aureus has also led to discussion of this pathogen in recent revisions of the international CAP guidelines. This pathogen is important because of its resistance to antibiotics commonly recommended for the empirical treatment of CAP and the association with a rapidly fatal form of pneumonia characterized by tissue necrosis, pulmonary hemorrhage, and rapid progression to respiratory failure. In tropical regions of Australia and Asia, CAP due to Acinetobacter baumannii is also increasingly recognized. This review discusses their recent epidemiology, microbiology, clinical features, and treatment of CAP caused by these antimicrobial-resistant pathogens. © 2009 American College of Chest Physicians.en_US
dc.languageengen_US
dc.publisherAmerican College of Chest Physicians. The Journal's web site is located at http://www.chestjournal.orgen_US
dc.relation.ispartofChesten_US
dc.subject.meshAcinetobacter Infections - Drug Therapyen_US
dc.subject.meshAcinetobacter Baumanniien_US
dc.subject.meshCommunity-Acquired Infections - Drug Therapy - Microbiologyen_US
dc.subject.meshDrug Resistance, Microbialen_US
dc.subject.meshHumansen_US
dc.subject.meshMethicillin Resistanceen_US
dc.subject.meshPneumonia - Drug Therapy - Microbiologyen_US
dc.subject.meshPneumonia, Pneumococcal - Drug Therapyen_US
dc.subject.meshStaphylococcal Infections - Drug Therapyen_US
dc.titleAntibiotic resistance in community-acquired pneumonia caused by Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus, and Acinetobacter baumanniien_US
dc.typeArticleen_US
dc.identifier.emailHo, PL:plho@hkucc.hku.hken_US
dc.identifier.authorityHo, PL=rp00406en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1378/chest.09-0285en_US
dc.identifier.pmid19809053-
dc.identifier.scopuseid_2-s2.0-70350112416en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-70350112416&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume136en_US
dc.identifier.issue4en_US
dc.identifier.spage1119en_US
dc.identifier.epage1127en_US
dc.identifier.isiWOS:000270855500029-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridHo, PL=7402211363en_US
dc.identifier.scopusauthoridCheng, VCC=23670479400en_US
dc.identifier.scopusauthoridChu, CM=7404345558en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats